TAPENTADOL
Clinical safety rating: safe
Animal studies have demonstrated safety
Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.
| Metabolism | Extensively metabolized via conjugation (primarily glucuronidation) and by CYP2C9 and CYP2C19 to a minor extent. Major metabolites are inactive. |
| Excretion | Primarily renal: approximately 95% of the dose is excreted in urine (60% as tapentadol glucuronide, 15% as unchanged tapentadol, and 20% as other metabolites); less than 3% excreted in feces. |
| Half-life | Terminal elimination half-life is approximately 4 hours (range 3-5 hours) for immediate-release; for extended-release, effective half-life is about 4-6 hours due to prolonged absorption. |
| Protein binding | Approximately 20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 540 L (approximately 7.7 L/kg for a 70 kg adult), indicating extensive tissue distribution. |
| Bioavailability | Oral: approximately 32% due to first-pass metabolism; intravenous: 100%. |
| Onset of Action | Immediate-release: 30-60 minutes; Extended-release: not applicable (designed for sustained effect). |
| Duration of Action | Immediate-release: 4-6 hours; Extended-release: 12 hours. Analgesic effect correlates with plasma concentrations. |
| Molecular Weight | 221.34 |
Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Creatinine clearance (CrCl) 30-80 mL/min: No adjustment needed. CrCl <30 mL/min: Not recommended (extended-release) or use with caution and reduce dose by 50% (immediate-release). Hemodialysis: Not recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and increase dosing interval to every 8 hours (immediate-release) or every 12 hours (extended-release). Child-Pugh Class C: Contraindicated. |
| Pediatric use | Safety and efficacy not established in children <18 years; not recommended. |
| Geriatric use | Start at low end of dosing range; monitor for CNS effects, constipation, and respiratory depression. Immediate-release: 50 mg every 6 hours initially; extended-release: not recommended for opioid-naïve elderly. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at therapeutic doses but increased ossification delays at high doses. Avoid unless benefits outweigh risks. |
| 2nd trimester | No evidence of fetal harm from limited studies; however, prolonged use may cause neonatal opioid withdrawal. Use only if clearly needed. |
| 3rd trimester | Prolonged use may cause neonatal opioid withdrawal syndrome; risk of respiratory depression at delivery. Avoid use near term. |
Clinical note
CNS depressants including alcohol and benzodiazepines increase sedation risk MAOIs can cause serotonin syndrome.
| Placental transfer | Tapentadol crosses the placenta; umbilical cord plasma concentrations are ~80% of maternal plasma levels at delivery. |
| Breastfeeding | Tapentadol is excreted into breast milk in low levels (milk:plasma ratio ~1.3). A study reported relative infant dose of 0.8% of maternal weight-adjusted dose. Monitor infant for sedation and respiratory depression; benefit likely outweighs risk with short-term use. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with drugs affecting cytochrome P450 isoenzymes.
| Common Effects | Constipation |
| Serious Effects |
Significant respiratory depressionAcute or severe bronchial asthma in an unmonitored settingKnown or suspected gastrointestinal obstruction (including paralytic ileus)Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapyHypersensitivity to tapentadol or any component of the formulation
| Precautions | Addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; seizures; risk of serotonin syndrome; adrenal insufficiency; and withdrawal. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data but potential for adverse effects in infants; use caution with prolonged or high doses. |
| Teratogenic Risk | First trimester: Limited data, no clear evidence of major malformations in humans, but opioid use associated with neural tube defects in some studies. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use near term due to risk of respiratory depression at birth. |
| Fetal Monitoring | Monitor for maternal sedation, respiratory depression, and constipation. Fetal monitoring: assess fetal growth and amniotic fluid volume if used chronically. Neonatal monitoring: observe for signs of opioid withdrawal (e.g., tremors, irritability, poor feeding) following prolonged in utero exposure. |
| Fertility Effects | Animal studies show no significant impairment of fertility at therapeutic doses. In humans, chronic opioid use may disrupt hormonal regulation (e.g., decreased libido, menstrual irregularities) but effects are reversible upon discontinuation. |
| Food/Dietary |
| No specific food interactions. Alcohol should be avoided due to additive CNS depressant effects. |
| Clinical Pearls | Tapentadol is a dual-mechanism opioid agonist and norepinephrine reuptake inhibitor. It has a lower incidence of opioid-induced nausea and vomiting compared to morphine. Avoid use in patients with severe hepatic impairment. Maximum daily dose is 600 mg. Do not crush extended-release tablets. Discontinuation should be gradual to avoid withdrawal. Serotonin syndrome risk when combined with serotonergic agents. |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Do not crush, chew, or dissolve tablets; swallow whole. · Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase risk of serious side effects like respiratory depression. · Dizziness or drowsiness may occur; avoid driving or operating machinery until you know how the medication affects you. · Do not stop abruptly; taper dose under medical supervision to prevent withdrawal symptoms. · Common side effects include nausea, vomiting, constipation, dizziness, and headache. · Report symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heartbeat, fever, muscle stiffness) immediately. · Keep out of reach of children; misuse can cause overdose and death. |